Biorem (BRM.V): The US$36M Canadian Company That Sells Bacteria, and Scored a Perfect StockRank of 100

A city needs to expand its sewage treatment plant. The engineering is routine, the money is budgeted, and the need is not in dispute. Then the neighbours find out, and the only thing they want to talk about is the smell.

This is where a very small Canadian company makes its living. Regulators will not grant the permit without a credible odour control plan, and $BRM.V, Biorem Inc sells the plan that works. Revenue has compounded at 14 percent over the last three years, return on equity is 43 percent, the share price is up 80 percent in twelve months, and the factor framework scores it StockRank 100 of 100, the highest number we can award. The market capitalisation is US$36 million.

Those two facts, a perfect score and a market cap smaller than many single office buildings, are the entire reason this company is interesting and the entire reason it requires care.

The Product: Bacteria That Eat Hydrogen Sulfide

Biorem makes air pollution control systems, and its core answer to foul air is biological rather than chemical. Contaminated air is drawn through beds of engineered media where colonies of bacteria consume hydrogen sulfide, the compound responsible for the rotten-egg smell that generates the complaint calls. There are no chemicals trucked to site, no drums to store, no hazardous handling procedure for staff. The inputs are air, water, and time.

That framing matters commercially, not just environmentally. A chemical scrubber is an ongoing purchase order, a delivery schedule, and a safety file. A biological bed is a capital item that then largely gets on with it. For a municipal utility running on a fixed operating budget with a small maintenance crew, the second proposition is much easier to live with for twenty years.

Small Ticket, High Consequence

The odour control system is a tiny fraction of the total cost of a wastewater project. It is also the component without which the permit does not issue and the project does not proceed.

Small ticket, high consequence. The cheapest line item on the page, holding up every other line item on the page.

This is one of the most reliable shapes in industrial investing, and it shows up wherever a low-cost input carries a catastrophic failure mode. Nobody value engineers the component that can void the permit, delay commissioning by a year, and put the utility on the front page of the local paper. The buyer's incentive is to specify the option most likely to work, and price discipline arrives a distant second. We looked at the large-cap version of exactly this dynamic in our piece on Linde and industrial gases, where the gas is a rounding error in the customer budget and an existential problem if it stops.

Twenty Years Versus Three: How the Spec Gets Won

Biorem's BIOSORBENS media is engineered to last about twenty years. Competing organic media, typically wood chips or compost based, degrades and has to be dug out and replaced every three to five years.

Consider what that means to the person evaluating bids. Excavating and replacing a media bed inside a live treatment plant is not a maintenance task, it is a small project: labour, disposal, downtime, and an odour event while the bed is open. Over a twenty-year asset life the rival product incurs that four to six times. Biorem incurs it approximately never. Even where Biorem is more expensive on day one, the life-cycle number is not close, and life-cycle cost is the number that wins the specification.

Winning the spec is the whole game here, and it is worth being precise about why.

Underwriting Live Biology

Biorem does something that sounds unremarkable until you think about it for a minute: it guarantees performance. It will contract to 99 percent plus removal efficiency, and it will hold that number through a Canadian winter and through a July heat wave.

The system is a living colony of bacteria. Its throughput depends on temperature, humidity, loading, and the chemistry of whatever the city sends down the sewer that week. Promising a fixed removal rate on a biological process, across that range of conditions, is much closer to writing an insurance policy than to selling a pump. The company is underwriting live biology.

An insurer can only price a policy because it has loss history. Biorem has three decades of commissioning data across roughly 2,000 installations: what the bed actually did, in what climate, on what feed, over what period. Those files are its actuarial tables. A competitor with a capable engineering team can copy the vessel, the media geometry, and the control logic in a year. It cannot copy thirty years of knowing what happens at minus 30 degrees in year eleven. That gap is the reason Biorem can sign a guarantee a newcomer would be reckless to sign, and the guarantee is what the consulting engineer is buying.

In Hamilton Helmer's vocabulary this sits between Process Power and a Cornered Resource: an accumulated operating dataset that only time can produce. Our explainer on what an economic moat actually is covers why advantages built out of elapsed time tend to be the most durable ones.

How a US$36M Company Survives a US$27B One

The obvious objection is Xylem, a US$27 billion water technology group, and the other large players in municipal water. How does a company worth 0.1 percent of that survive in the same tender?

The answer is that the municipal utility does not choose the vendor. The consulting engineer writes the specification, and the utility buys what the specification describes. Consulting engineers are, by professional temperament and by liability exposure, conservative people. They reuse specifications that survived commissioning, because a spec that worked last time is defensible and a novel one is a career risk.

So the sales motion is not really persuading a buyer, it is being the language the spec is written in. Roughly 2,000 installations across North America means Biorem is a known, referenceable contractor with a track record any engineer can check. A giant with a superior balance sheet does not automatically displace that, because the incumbent advantage is not price, it is the absence of any reason to change.

It is a narrow niche and a real one. The same structure shows up in Frontken, where being qualified into a customer process is worth more than being cheaper than the alternative.

Where the Growth Is Coming From

Two lines, and both are sensible extensions of an existing channel rather than adventures into new ones.

• Non-biological systems, since 2022. The same sales channel now also carries products such as dry scrubbers. The engineer who already trusts Biorem for the biological bed can now buy the adjacent equipment from the same supplier, which raises revenue per project without requiring a new relationship.
• Services, and this is the interesting one. A newly established services team chases recurring revenue after every delivery. It has reached 33 percent of sales in the latest quarter, against 7 percent a year earlier.

That services number deserves emphasis. A project business is lumpy, backlog-dependent, and valued accordingly. A business where a third of revenue is recurring service on an installed base of 2,000 systems is a structurally different and better animal. If that mix holds, the earnings quality improves in a way the trailing multiple does not yet reflect. If it was a one-quarter artefact of project timing, it does not. This is the single line item to track in the next few statements.

Capital Return: Nothing Yet, and That Is a Choice

Shareholders have received nothing back. There have been no dividends to date. A buyback for 5 percent of shares was approved in June 2025, and only around US$100,000 has actually been spent under it, which on this market cap is a gesture rather than a programme.

Cash is instead funding a growing order book. At this stage of this company's life that is defensible and probably correct: a business with a rising backlog and 43 percent returns on equity should be putting capital into the backlog, not buying stock. Working capital for project delivery is a genuine use of funds.

The honest counterpoint is that an approved buyback that goes almost entirely unused is a slightly awkward artefact. It signals an intention that was not acted on. Our guide to reading these programmes, how to tell a real buyback from an announced one, exists precisely because authorisation and execution are very different events.

The MoatMap Scorecard: Q88 V63 M87, StockRank 100

Here is the Biorem MoatMap StockRank:

• Quality: 88/100. Excellent, and earned rather than flattered. A 43 percent ROE with a clean balance sheet, on a business with genuine specification lock-in, is what the Quality factor is built to find.
• Value: 63/100. Reasonable. Not a deep value screen result, and after an 80 percent move it would be strange if it were, but comfortably above the midpoint. The market has noticed and has not yet priced it as a compounder.
• Momentum: 87/100. Strong, driven by the price move and by earnings actually delivering underneath it.
• Composite StockRank: 100/100. The maximum. This is what happens when all three factors point the same way at once: high quality, not expensive, and working. It is rare, and it is the whole reason the name surfaced.

A perfect composite is a statement about factor alignment, not a prediction. It says that on Quality, Value and Momentum together, nothing in a universe of more than 20,000 stocks currently scores better. It does not say the business cannot disappoint. Our guide to factor investing sets out what a composite of this kind is and is not claiming, and the wider market context sits in Best Canadian Stocks 2026.

The Question Worth Sitting With

In December 2025 the CEO sold 28 percent of his direct holding. The business then printed two of its best quarters on record.

The generous reading is the standard one, and it is usually true: insiders sell for all kinds of reasons that have nothing to do with the outlook. Tax, a house, a divorce, diversification after a stock has doubled. A single sale is weak evidence about anything, which is why we treat isolated sells very differently from clustered buys. Our note on reading insider transactions explains why the asymmetry is real: there is one reason to buy and many reasons to sell.

The uncomfortable reading is simply that the person with the best information reduced exposure by more than a quarter immediately before the strongest operating results the company has produced. That is not a scandal. It is a data point, and the sequence is worth remembering rather than explaining away.

Then there is size. At US$36 million this is a genuine microcap on the TSX Venture Exchange, with everything that implies: thin liquidity, a wide spread, minimal analyst coverage, and a share price that can move a long way on a single institutional order. Customer concentration is a live risk when revenue arrives in lumpy municipal projects, and a single delayed commissioning can reshape a quarter.

The founder's own framing of the opportunity is that at current valuations the stock could rise thirteen times over and still be worth less than US$500 million. That is a statement about how small the company is today rather than a forecast, and it cuts both ways. Enormous room to grow into is also the reason nobody large is required to take the other side of the trade.

Companion Reading

Biorem sits inside our industrial and specification-lock cluster with three close neighbours:

• Linde (LIN) is the same economics at a thousand times the size: a product that is trivial as a share of customer cost and catastrophic when it fails, sold on long contracts into processes nobody wants to re-engineer.
• Frontken (0128.KL) for the qualification barrier in another industry: once you are written into a customer process, being replaced requires them to take a risk they have no reason to take.
• Azeus Systems (BBW.SI) for the microcap parallel: a very small listed company whose real asset is a reference list and a reputation for never having failed, with the liquidity and coverage limits that come with the size.

The Bottom Line

Biorem sells the least glamorous product on the page and occupies one of the better competitive positions we have looked at recently. Demand is created by regulation rather than by fashion, the buying decision is made by a conservative engineer who reuses what worked, the media lasts twenty years against a rival's three to five, and the performance guarantee that closes the sale rests on three decades of commissioning data a competitor cannot buy at any price.

The scorecard is the rarest configuration we publish: Quality 88, Value 63, Momentum 87, composite 100. The services line moving from 7 percent to 33 percent of sales is the development that would justify a permanently different multiple, and it is the number to watch. Set against that is a US$36 million market cap with the liquidity that implies, a buyback authorised and then left almost entirely unspent, no dividend, and a CEO who trimmed a quarter of his direct stake just before two record quarters.

For sizing a position where the business quality is strong and the market cap is small enough to matter, our guide to reviewing your portfolio for weak spots is the relevant framework. For the full breakdown including the backlog, the services mix, the segment economics and the valuation walk, the Biorem Deep Dive is the place to go.

This article is for informational purposes only and is not investment advice. The author may be long names covered on MoatMap.